Company
Official Name: Roche Holding AG
Headquarters: Basel, Switzerland
Employees: 100,920
CEO: Dr. Severin Schwan Ph.D.
CHF239.95 Billion
CHF as of Jan. 1, 2023
US$259.51 Billion
Company | Market Cap (USD) |
---|---|
![]() |
$461.85 B |
![]() |
$347.61 B |
![]() |
$287.63 B |
![]() |
$285.80 B |
![]() |
$281.30 B |
Company | Market Cap (USD) |
---|---|
![]() |
$495.37 B |
![]() |
$461.85 B |
![]() |
$347.61 B |
![]() |
$304.61 B |
![]() |
$287.63 B |
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG has the following listings and related stock indices.
Stock: SIX: ROG
Stock: BMV: ROGN
Stock: OTC: RHHBF
Stock: OTC: RHHBY
Stock: OTC: RHHVF
Stock: SIX: RO
Stock: FSX: RHO6